Apricus Bio licenses ED drug Vitaros rights to Neopharm in Israel
In return, Apricus Bio is entitled to receive up to a total of $4.35m in up-front, regulatory and sales milestone payments for the products. Further, over the life
Biologics contract development and manufacturing organisation (CDMO) AsymBio is set to secure 1.2397bn yuan (approximately $184m) from Asymchem Group, Hillhouse Qirui and other investors to support its long-term growth.